title: Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study.
abstract: The modification of dopamine release and accumulation induced by gamma-hydroxybutyrate (GHB) was studied using both striatal slices and in vivo microdialysis of caudate-putamen. GHB inhibited dopamine release for approximately 5-10 min in vitro, and this was associated with an accumulation of dopamine in the tissue. Subsequently, there was an increase in dopamine release. In the microdialysis experiments, low doses of GHB inhibited dopamine release, whereas higher doses strongly increased release; the initial decrease seen in slices could not be detected in vivo. Thus, GHB had a biphasic effect on the release of dopamine: An initial decrease in the release of transmitter was followed by an increase. A time-dependent biphasic effect was observed when GHB was added to brain slices, and a dose-dependent biphasic effect was seen in dialysate after systemic administration of GHB. Naloxone blocked GHB-induced dopamine accumulation and release both in vitro and in vivo. GHB also increased the release of opioid-like substances in the striatum. A specific antagonist of GHB receptors completely blocked both the dopamine response and the release of opioid-like substances. These data suggest that GHB increases dopamine release via specific receptors that may modulate the activity of opioid interneurons.
authors.affiliation: Centre de Neurochemie du CNRS, Strasbourg, France.
authors.forename: V
authors.initials: V
authors.lastname: Hechler
authors.forename: S
authors.initials: S
authors.lastname: Gobaille
authors.forename: J J
authors.initials: JJ
authors.lastname: Bourguignon
authors.forename: M
authors.initials: M
authors.lastname: Maitre
mesh_terms: D000287:Administration, Topical; D000818:Animals; D001567:Benzocycloheptenes / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003956:Dialysis / Q000379:methods; D004298:Dopamine / Q000378:metabolism; D004723:Endorphins / Q000378:metabolism; D005110:Extracellular Space / Q000187:drug effects*; D058787:GABA-A Receptor Antagonists; D066298:In Vitro Techniques; D007274:Injections, Intraperitoneal; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface; D012978:Sodium Oxybate / Q000494:pharmacology*; D013779:Tetrodotoxin / Q000494:pharmacology
chemical_list: C039403:4-hydroxybutyric acid receptor; D001567:Benzocycloheptenes; D004723:Endorphins; D058787:GABA-A Receptor Antagonists; D011956:Receptors, Cell Surface; C066471:NCS 382; D013779:Tetrodotoxin; D012978:Sodium Oxybate; D002118:Calcium; D004298:Dopamine